Psychedelics and entactogens have shown promise for the treatment of psychiatric disorders in clinical trials, and psilocybin appears to be moving toward Food and Drug Administration approval. alert.psychnews.org/adults-who-used…
alert.psychnews.org
Adults Who Used Ibogaine or 5-MeO-DMT as Likely to Report Harms as Help
Most U.S. adults have experienced at least one significant adverse outcome such as chest pain, memory problems, paranoia, or suicidal thoughts after using psychedelic or entactogen drugs.